Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889498 | 0.93 | PI4KB (0.72) | PI4KBKCNH2CHRM2EPHX2NTRK1 | |
| SCHEMBL17889449 | 0.92 | PI4KB (0.83) | PI4KBKCNH2CHRM2EPHX2KIT | |
| SCHEMBL17889437 | 0.91 | PI4KB (0.84) | PI4KBKCNH2 | |
| SCHEMBL17889446 | 0.84 | PI4KB (0.68) | PI4KBKCNH2KITTRPV1 | |
| SCHEMBL17889451 | 0.84 | PI4KB (0.84) | PI4KBKCNH2KITTRPV1 | |
| SCHEMBL17889375 | 0.83 | PI4KB (0.69) | PI4KBKCNH2NTRK1KRASTRPV1 | |
| SCHEMBL17889492 | 0.83 | PI4KB (0.69) | PI4KBKCNH2NTRK1TRPV1 | |
| SCHEMBL18788203 | 0.83 | PI4KB (0.51) | PI4KBKCNH2CHRM2EPHX2NTRK1 | |
| SCHEMBL17889380 | 0.83 | PI4KB (0.69) | PI4KBKCNH2CHRM2EPHX2KIT | |
| SCHEMBL17889431 | 0.83 | PI4KB (0.68) | PI4KBKCNH2EPHX2KITTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | claimed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | claimed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | PI4KB 275/4885KCNH2 3599/4885CHRM2 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.